Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Date

Click to order products descending

Display 45 Products per page

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Market Spotlight: Axial Spondyloarthritis (axSpA)

$1,318.00

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Market Spotlight: Endometriosis

$1,318.00

This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Market Spotlight: Insomnia

$1,318.00

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Market Spotlight: Gout

$1,318.00

This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Market Spotlight: Thyroid Eye Disease (TED)

$1,318.00

Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
March 17, 2022
Find out more
Market Spotlight: Sickle Cell Anemia

$1,318.00

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
March 17, 2022
Find out more
Market Spotlight: Fibromyalgia

$1,318.00

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, prevalence data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Market Spotlight: Basal Cell Carcinoma

$1,318.00

This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Market Spotlight: Erectile Dysfunction

$1,318.00

This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Drug Delivery: Injection Devices

$4,750.00

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn.
March 15, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – Italy

$599.00

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.
March 14, 2022
Find out more
Market Spotlight: Hepatitis B

$1,318.00

This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – US, South

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Market Spotlight: Obesity

$1,318.00

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 14, 2022
Find out more
Market Spotlight: Fragile X Syndrome

$1,318.00

This Market Spotlight report covers the Fragile X Syndrome market, comprising key pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a discussion on disease epidemiology, and licensing and asset acquisition deals.
March 11, 2022
Find out more
Disease Analysis: Diabetic Nephropathy
Read More
Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.
March 11, 2022
Find out more
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

$1,318.00

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
March 10, 2022
Find out more
Market Spotlight: Duchenne Muscular Dystrophy (DMD)

$1,318.00

This Market Spotlight report covers the Duchenne Muscular Dystrophy (DMD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 10, 2022
Find out more
Disease Analysis: NHL: Follicular Lymphoma
Read More
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.
March 10, 2022
Find out more
Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 10, 2022
Find out more
Market Spotlight: Myelodysplastic Syndrome (MDS)

$1,318.00

This Market Spotlight report covers the Myelodysplastic Syndrome (MDS) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 9, 2022
Find out more
Disease Analysis: Hepatitis C
Read More
Hepatitis C is a liver disease caused by chronic infection with hepatitis C virus (HCV), a hepacivirus belonging to the Flaviviridae family. HCV infects hepatocytes and is the leading cause of cirrhosis and hepatocellular cancer (HCC). Approximately 15−45% of people infected with HCV will spontaneously clear the virus, but the remaining 55−85% will develop chronic HCV infection. For those chronically infected with HCV, the risk of cirrhosis increases by 15–30% within 20 years.
March 9, 2022
Find out more
Market Spotlight: Cachexia

$1,318.00

Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.
March 8, 2022
Find out more
Market Spotlight: Pancreatic Cancer

$1,318.00

This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 4, 2022
Find out more
Market Spotlight: Small-Cell Lung Cancer (SCLC)

$1,318.00

This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 4, 2022
Find out more
Market Spotlight: Osteoarthritis and Osteoarthritis Pain

$1,318.00

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
March 4, 2022
Find out more
Disease Analysis: Prostate Cancer
Read More
Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.
March 2, 2022
Find out more
Disease Analysis: Colorectal Cancer
Read More
Colorectal (or bowel) cancer refers to carcinomas arising in the epithelium of the large intestine at any point between the cecal valve and the anus. CRC typically develops through the proliferation of mucosal epithelial cells of the gastrointestinal (GI) wall, eventually forming a polyp or adenoma. As with many other cancers of the GI tract, the vast majority (>95%) are adenocarcinomas.
March 1, 2022
Find out more
Market Spotlight: Cold Agglutinin Disease

$1,318.00

Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.
February 28, 2022
Find out more
Market Spotlight: Opioid-Induced Constipation

$1,318.00

This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.
February 28, 2022
Find out more
Market Spotlight: Glaucoma

$1,318.00

This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
February 28, 2022
Find out more
Melanoma KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.
February 25, 2022
Find out more
Disease Analysis: Melanoma
Read More
Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.
February 25, 2022
Find out more
Disease Analysis: Chronic Myeloid Leukemia (CML)
Read More
Chronic myeloid leukemia (CML) is defined as a cancer of the blood in which a mutation in myeloid hematopoietic stem cells causes the overproduction of immature and dysfunctional white blood cells (myeloblasts, also known as blasts), preventing the normal production and function of healthy white blood cells, red blood cells, and platelets.
February 25, 2022
Find out more
Melanoma KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.
February 25, 2022
Find out more
Disease Analysis: Triple-Negative Breast Cancer
Read More
Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.
February 24, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
February 24, 2022
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
February 24, 2022
Find out more
Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)
Read More
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.
February 23, 2022
Find out more
Neuromodulation: Spinal Cord Stimulation Devices Market

$4,750.00

According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain.
February 22, 2022
Find out more
Disease Analysis: COVID-19 Prevention
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus
February 21, 2022
Find out more
Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)

$1,318.00

This Market Spotlight report covers the Amyotrophic Lateral Sclerosis (ALS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals.
February 18, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *